Skiplinks


Breadcrumb

[G09-01] Health economic evaluation of venlafaxine, duloxetine, bupropion, and mirtazapine compared to further prescribable pharmaceutical treatments

Overview

Overview

Commission:Commission awarded on 2009-12-17 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department:Health Economics
Current document:PDFExecutive summary of the final report [PDF, 293 kB]Further documents
Contact address:to the contact form


Report documents

Report documents

PublishedDocumentSizeType 
2013-10-30Executive summary of the final report293 kBPDFdownload file
2013-10-30Final report (German version)5 MBPDFdownload file
2013-10-30Documentation and evaluation of comments on the preliminary report (German version)2 MBPDFdownload file
2012-11-19Executive summary of the preliminary report (German version)318 kBPDFdownload file
2012-11-19Preliminary report (German version)5 MBPDFdownload file
2012-11-19Annex 1 to the preliminary report (German version) Calculation tool for determining costs 635 kBPDFdownload file
2012-11-19Annex 2 to the preliminary report (German version) Cost-benefit assessment model (TreeAge file)27 kBZIPdownload file
2011-05-17Report plan version 1.0 (German version)432 kBPDFdownload file
2011-05-17Documentation and appraisal of comments on the preliminary report plan (German version)4 MBPDFdownload file
2010-10-26Preliminary report plan (German version)371 kBPDFdownload file

At a glance


to top

Glossary entries